Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy

Overview

Journal AAPS J

Specialty Pharmacology

Date 2012 Mar 13

PMID 22407289

Citations 128

Authors

Narendra Chirmule

Vibha Jawa

Bernd Meibohm

Affiliations

Soon will be listed here.

Abstract

The development of therapeutic proteins requires the understanding of the relationship between the dose, exposure, efficacy, and toxicity of these molecules. Several intrinsic and extrinsic factors contribute to the challenges for measuring therapeutic proteins in a precise and accurate manner. In addition, induction of an immune response to therapeutic protein results in additional complexities in the analysis of the pharmacokinetic profile, toxicity, safety, and efficacy of this class of molecules. Assessment of immunogenicity of therapeutic proteins is a required aspect of regulatory filings for a licensing application and for the safe and efficacious use of these compounds. A systematic strategy and well-defined criteria for measuring anti-drug antibodies (ADA) have been established, to a large extent, through coordinated efforts. These recommendations are based on risk assessment and include the determination of ADA content (concentration/titer), affinity, immunoglobulin isotype/subtype, and neutralization capacity. This manuscript reviews the requirements necessary for understanding the nature of an ADA response in order to discern the impact of immunogenicity on pharmacokinetics/pharmacodynamics and efficacy.

Citing Articles

Clinical evidence of immunogenicity of CAR-T cell therapies and its implication in the clinical development of CAR-T drug products.

Alfar H, Chen C, Lachacz E, Tang W, Zhang Y Front Immunol. 2025; 16:1512494.

PMID: 40061940 PMC: 11885493. DOI: 10.3389/fimmu.2025.1512494.

Effect of E7777 Immunogenicity on Pharmacokinetics, Efficacy, and Safety in Adult Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.

Thway T, Aluri J, Lalovic B, Ooi C, Sauter N, Xing D Clin Transl Sci. 2025; 18(3):e70166.

PMID: 40009571 PMC: 11864228. DOI: 10.1111/cts.70166.

Therapeutic drug monitoring and immunogenetic factors associated with the use of adalimumab in Crohn's disease patients.

Genaro L, Carron J, de Castro M, Franceschini A, Lourenco G, Cruz C Int J Immunopathol Pharmacol. 2025; 39:3946320251319379.

PMID: 39959979 PMC: 11831650. DOI: 10.1177/03946320251319379.

Stability of Anti-Drug Antibodies Against Antibody Therapeutics.

Sirohi P, Hainline K, Bullock H, Wang S, Konrad R, Wen Y AAPS J. 2025; 27(1):45.

PMID: 39953303 DOI: 10.1208/s12248-025-01030-z.

What are clinically significant anti-drug antibodies and why is it important to identify them.

Swanson S Front Immunol. 2024; 15:1401178.

PMID: 39737166 PMC: 11682980. DOI: 10.3389/fimmu.2024.1401178.

References

Patton A, Mullenix M, Swanson S, Koren E . An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J Immunol Methods. 2005; 304(1-2):189-95. DOI: 10.1016/j.jim.2005.06.014. View

Kishnani P, Goldenberg P, DeArmey S, Heller J, Benjamin D, Young S . Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2009; 99(1):26-33. PMC: 3721340. DOI: 10.1016/j.ymgme.2009.08.003. View

Hansel T, Kropshofer H, Singer T, Mitchell J, George A . The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010; 9(4):325-38. DOI: 10.1038/nrd3003. View

Gupta S, Devanarayan V, Finco D, Gunn 3rd G, Kirshner S, Richards S . Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. J Pharm Biomed Anal. 2011; 55(5):878-88. DOI: 10.1016/j.jpba.2011.03.038. View

Banugaria S, Prater S, Ng Y, Kobori J, Finkel R, Ladda R . The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med. 2011; 13(8):729-36. PMC: 3954622. DOI: 10.1097/GIM.0b013e3182174703. View

Schellekens H . Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov. 2002; 1(6):457-62. DOI: 10.1038/nrd818. View

Barbosa M, Vielmetter J, Chu S, Smith D, Jacinto J . Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. Clin Immunol. 2005; 118(1):42-50. DOI: 10.1016/j.clim.2005.08.017. View

Tabrizi M, Roskos L . Preclinical and clinical safety of monoclonal antibodies. Drug Discov Today. 2007; 12(13-14):540-7. DOI: 10.1016/j.drudis.2007.05.010. View

Millonig A, Rudzki D, Holzl M, Ehling R, Gneiss C, Kunz B . High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study. Mult Scler. 2009; 15(8):977-83. DOI: 10.1177/1352458509105384. View

10.

Dong J, Salinger D, Endres C, Gibbs J, Hsu C, Stouch B . Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet. 2011; 50(2):131-42. DOI: 10.2165/11537430-000000000-00000. View

11.

Collins P, Mathias M, Hanley J, Keeling D, Keenan R, Laffan M . Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort. J Thromb Haemost. 2009; 7(5):787-94. DOI: 10.1111/j.1538-7836.2009.03332.x. View

12.

Bartelds G, Krieckaert C, Nurmohamed M, van Schouwenburg P, Lems W, Twisk J . Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011; 305(14):1460-8. DOI: 10.1001/jama.2011.406. View

13.

Bautista A, Wullner D, Moxness M, Swanson S, Chirmule N, Jawa V . Impact of matrix-associated soluble factors on the specificity of the immunogenicity assessment. Bioanalysis. 2010; 2(4):721-31. DOI: 10.4155/bio.10.24. View

14.

Jawa V, Hokom M, Hu Z, El-Abaadi N, Zhuang Y, Berger D . Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects. Ann Hematol. 2010; 89 Suppl 1:75-85. PMC: 2900600. DOI: 10.1007/s00277-010-0908-2. View

15.

Carpenter J, Cherney B, Lubinecki A, Ma S, Marszal E, Mire-Sluis A . Meeting report on protein particles and immunogenicity of therapeutic proteins: filling in the gaps in risk evaluation and mitigation. Biologicals. 2010; 38(5):602-11. DOI: 10.1016/j.biologicals.2010.07.002. View

16.

Lecluse L, Driessen R, Spuls P, de Jong E, Stapel S, van Doorn M . Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol. 2010; 146(2):127-32. DOI: 10.1001/archdermatol.2009.347. View

17.

Rathore A, Winkle H . Quality by design for biopharmaceuticals. Nat Biotechnol. 2009; 27(1):26-34. DOI: 10.1038/nbt0109-26. View

18.

Rehlaender B, Cho M . Antibodies as carrier proteins. Pharm Res. 1998; 15(11):1652-6. DOI: 10.1023/a:1011936007457. View

19.

Liang M, Klakamp S, Funelas C, Lu H, Lam B, Herl C . Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms. Assay Drug Dev Technol. 2007; 5(5):655-62. DOI: 10.1089/adt.2007.089. View

20.

Salimi-Moosavi H, Lee J, DeSilva B, Doellgast G . Novel approaches using alkaline or acid/guanidine treatment to eliminate therapeutic antibody interference in the measurement of total target ligand. J Pharm Biomed Anal. 2009; 51(5):1128-33. DOI: 10.1016/j.jpba.2009.11.021. View